Last 12 months
Inside the activity.
0 purchase rows · 38 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 22 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
Sandberg EricChief Commercial Officer
|
Tax withholdingCommon Stock | 936 | $14.68 | $13,740.48 |
DisclosureSEC source: 0001179110-20-001945 · edgar.xml · nonDerivative · entry 2 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,595 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
Sandberg EricChief Commercial Officer
|
GrantCommon Stock | 2,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001945 · edgar.xml · nonDerivative · entry 1 Sandberg Eric · CIK 0001764446 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,531 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
Tax withholdingCommon Stock | 351 | $14.68 | $5,152.68 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,526 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,877 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
Tax withholdingCommon Stock | 1,498 | $14.68 | $21,990.64 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,696 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 5,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001943 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,194 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
Freitag Gregory GeneDirector · General Counsel
|
Tax withholdingCommon Stock | 529 | $14.68 | $7,765.72 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 4 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,484 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
Freitag Gregory GeneDirector · General Counsel
|
GrantCommon Stock | 1,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 3 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,013 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
Freitag Gregory GeneDirector · General Counsel
|
Tax withholdingCommon Stock | 1,002 | $14.68 | $14,709.36 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,230 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:19 UTC |
Freitag Gregory GeneDirector · General Counsel
|
GrantCommon Stock | 3,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001944 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,232 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC |
Billet IsabelleChief Strategy and BD Officer
|
Tax withholdingCommon Stock | 440 | $14.68 | $6,459.20 |
DisclosureSEC source: 0001179110-20-001942 · edgar.xml · nonDerivative · entry 2 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,521 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC |
Billet IsabelleChief Strategy and BD Officer
|
GrantCommon Stock | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001942 · edgar.xml · nonDerivative · entry 1 Billet Isabelle · CIK 0001756302 · Chief Strategy and BD Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,961 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
Tax withholdingCommon Stock | 394 | $14.68 | $5,783.92 |
DisclosureSEC source: 0001179110-20-001941 · edgar.xml · nonDerivative · entry 2 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,932 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 18, 2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 18:18 UTC |
MARTINEZ MARIA D.Chief Human Resources Officer
|
GrantCommon Stock | 1,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001941 · edgar.xml · nonDerivative · entry 1 MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,326 F1 · shares: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. F1 · price: This reflects the number of shares that became vested as of February 18, 2020 upon the attainment of certain performance criteria. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 13:03 UTC |
Rudelius Robert JamesDirector
|
Exercise / conversionDirector Stock Option (right to purchase) · Derivative | 13,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001179110-20-000065 · edgar.xml · derivative · entry 3 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2020-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 13:03 UTC |
Rudelius Robert JamesDirector
|
Tax withholdingCommon Stock | 1,999 | $17.89 | $35,762.11 |
DisclosureSEC source: 0001179110-20-000065 · edgar.xml · nonDerivative · entry 2 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,592 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 13,000 shares by means of a cashless exercise. A cashless exercise is a method of exercising a stock option in which the option holder pays the exercise price using shares the reporting person would have received pursuant to the option exercise. As a result of this cashless exercise, the Reporting Person, on a net basis, acquired ownership of an additional 11,001 shares of common stock. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 13:03 UTC |
Rudelius Robert JamesDirector
|
Exercise / conversionCommon Stock | 13,000 | $2.75 | $35,750.00 |
DisclosureSEC source: 0001179110-20-000065 · edgar.xml · nonDerivative · entry 1 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 13,000 shares by means of a cashless exercise. A cashless exercise is a method of exercising a stock option in which the option holder pays the exercise price using shares the reporting person would have received pursuant to the option exercise. As a result of this cashless exercise, the Reporting Person, on a net basis, acquired ownership of an additional 11,001 shares of common stock. Read SEC document |
| January 01, 2020 Filed Jan 18, 2020 01:41 UTC |
Zaderej Karen L.Director · CEO
|
Disposition to issuerCommon Stock | 10,112 | $17.34 | $175,342.08 |
DisclosureSEC source: 0001179110-20-000664 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,680 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on January 1, 2020. Read SEC document |
| January 01, 2020 Filed Jan 18, 2020 01:41 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-000664 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,792 F1 · shares: This reflects the number of restricted stock units that became vested as of January 1, 2020. F1 · price: This reflects the number of restricted stock units that became vested as of January 1, 2020. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:28 UTC |
Zaderej Karen L.Director · CEO
|
GrantCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013087 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,530 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC |
MARIANI PETER JChief Financial Officer
|
Tax withholdingCommon Stock | 1,049 | $16.73 | $17,549.77 |
DisclosureSEC source: 0001179110-19-013084 · edgar.xml · nonDerivative · entry 2 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,433 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC |
MARIANI PETER JChief Financial Officer
|
GrantCommon Stock | 3,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013084 · edgar.xml · nonDerivative · entry 1 MARIANI PETER J · CIK 0001222357 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,482 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
Tax withholdingCommon Stock | 183 | $16.73 | $3,061.59 |
DisclosureSEC source: 0001179110-19-013086 · edgar.xml · nonDerivative · entry 2 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,127 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC |
Friedman Mark LouisVP,Regulatory & Quality
|
GrantCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013086 · edgar.xml · nonDerivative · entry 1 Friedman Mark Louis · CIK 0001531023 · VP,Regulatory & Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
Tax withholdingCommon Stock | 281 | $16.73 | $4,701.13 |
DisclosureSEC source: 0001179110-19-013085 · edgar.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,840 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:27 UTC |
DeVinney Erick WayneVP, Clinical&Translational Sc
|
GrantCommon Stock | 1,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013085 · edgar.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP, Clinical&Translational Sc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,121 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:16 UTC |
Donovan Michael PatrickVP Operations
|
Tax withholdingCommon Stock | 183 | $16.73 | $3,061.59 |
DisclosureSEC source: 0001179110-19-013083 · edgar.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,041 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:16 UTC |
Donovan Michael PatrickVP Operations
|
GrantCommon Stock | 750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013083 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,224 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:16 UTC |
Freitag Gregory GeneDirector · General Counsel
|
Tax withholdingCommon Stock | 567 | $16.73 | $9,485.91 |
DisclosureSEC source: 0001179110-19-013082 · edgar.xml · nonDerivative · entry 2 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,543 F2 · shares: The reported shares were withheld to cover the Reporting Person's tax withholding liability in connection with a portion of the restricted stock units that vested on December 18, 2019. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:16 UTC |
Freitag Gregory GeneDirector · General Counsel
|
GrantCommon Stock | 1,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-013082 · edgar.xml · nonDerivative · entry 1 Freitag Gregory Gene · CIK 0001492710 · Director · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,110 F1 · shares: This reflects the number of restricted stock units that became vested as of December 18, 2019. F1 · price: This reflects the number of restricted stock units that became vested as of December 18, 2019. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 01:40 UTC |
Gold Mark StephenDirector
|
GiftCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012473 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 326,771 F1 · balance_after: The shares of common stock for Dr. Gold include 192,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 192,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his adult children who do not share a household with Dr. Gold. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 23:03 UTC |
Gold Mark StephenDirector
|
GiftCommon Stock | 13,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012093 · edgar.xml · nonDerivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust-See Footnote Disclosed balance after: 333,771 F1 · balance_after: The shares of common stock for Dr. Gold include 199,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. F1 · ownership.direct: The shares of common stock for Dr. Gold include 199,671 shares held jointly by Dr. Gold and his wife, indirect ownership of 20,000 shares held by Dr. Gold's spouse and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust held by Dr. Gold's family. The transaction reflected on this Form 4 relates to the gift of securities by Dr. Gold to accounts held by his grandchildren pursuant to the Uniform Transfer to Minors Act who do not share a household with Dr. Gold. Read SEC document |
| October 08, 2019 Filed Oct 11, 2019 01:32 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001179110-19-010909 · edgar.xml · derivative · entry 4 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2020-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2019 Filed Oct 11, 2019 01:32 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001179110-19-010909 · edgar.xml · derivative · entry 3 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2019 Filed Oct 11, 2019 01:32 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 1,500 | $2.90 | $4,350.00 |
DisclosureSEC source: 0001179110-19-010909 · edgar.xml · nonDerivative · entry 2 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2019 Filed Oct 11, 2019 01:32 UTC |
Donovan Michael PatrickVP Operations
|
Exercise / conversionCommon Stock | 5,000 | $4.81 | $24,050.00 |
DisclosureSEC source: 0001179110-19-010909 · edgar.xml · nonDerivative · entry 1 Donovan Michael Patrick · CIK 0001653918 · VP Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:32 UTC |
Rudelius Robert JamesDirector
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010089 · edgar.xml · derivative · entry 2 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:32 UTC |
Rudelius Robert JamesDirector
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010089 · edgar.xml · derivative · entry 1 Rudelius Robert James · CIK 0001403679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 22:21 UTC |
Wendell Amy McBrideDirector
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010094 · edgar.xml · derivative · entry 2 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 22:21 UTC |
Wendell Amy McBrideDirector
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010094 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:31 UTC |
Gold Mark StephenDirector
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010088 · edgar.xml · derivative · entry 2 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:31 UTC |
Gold Mark StephenDirector
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010088 · edgar.xml · derivative · entry 1 Gold Mark Stephen · CIK 0001531332 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:09 UTC |
NEELS GUIDO JDirector
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010125 · edgar.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:09 UTC |
NEELS GUIDO JDirector
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010125 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:13 UTC |
Levine Alan MDirector
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010128 · edgar.xml · derivative · entry 2 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:13 UTC |
Levine Alan MDirector
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010128 · edgar.xml · derivative · entry 1 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:13 UTC |
Blackford Quentin S.Director
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010129 · edgar.xml · derivative · entry 2 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:13 UTC |
Blackford Quentin S.Director
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010129 · edgar.xml · derivative · entry 1 Blackford Quentin S. · CIK 0001612451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Jun 3, 2020 21:07 UTC |
Levine Alan MDirector
|
GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006915 · edgar.xml · derivative · entry 2 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Jun 3, 2020 21:07 UTC |
Levine Alan MDirector
|
GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-20-006915 · edgar.xml · derivative · entry 1 Levine Alan M · CIK 0001766833 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.